ATG5 and colorectal carcinoma: Through multiple Cox regression analyses with adjustments for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II), patients with higher ATG5 expression had shorter DFS in both CRC (AHR: 2.76, 95% CI: 1.49–4.82, p < 0.001) and DFS (AHR: 2.11, 95% CI: 1.25–3.54, p = 0.005, Table 1).